

April 1, 2015

# Apollo Global Management LLC

## Winter Is Coming: Sell APO Into 1Q Earnings

Industry View **In-Line**      Stock Rating **Underweight**      Price Target **\$23.00**

Lowering 1Q divi estimate by 38% to 30c; we're now 38% below consensus. Risk is that dividends may skew towards our bear case in 2015-16 with APO largely through its harvesting mode.

**Near-term we see downside risk to APO shares with our 30c dividend estimate in 1Q that is 38% below consensus and 64% lower than 1Q14's 84c div.** Our 2015 dividend of 1.96c is 6% below consensus and we see downside risk of ~36c if the cash performance fees held in Fund VI escrow are not released this year (we expect this is released in 4Q15, but if timing is pushed out then our 2015 divi declines to 1.60c which is 23% below consensus). While we see long-term value in APO, given the firm's strong track record of above average market returns, we think the stock will likely underperform peers over the next 12 months due to a declining cash earnings and dividend trajectory. Also see our 1Q Alts preview here: [US Asset Managers: Summer of Realizations: Buy BX and CG into 1Q Earnings \(01 Apr 2015\)](#).

**1Q divi expected to be the lowest since 2Q12.** If this trend persists, there could be a disconnect between near-term share-price performance and longer-term fundamentals. APO's high dividend yield (9.6% currently on cons 2015 divi) is a core part of the APO investment appeal in the short-term, until the outlook for cash earnings improves after another deployment cycle or incremental scaling of the credit business. We see downside risk to consensus dividend estimates and we're 6% below in 2015 (with downside bias to our estimate) and 13% below in 2016.

**No PE Monetizations Announced in 1Q:** APO did not announce any PE exits in 1Q in which they can take cash carry. Yes APO exited Sprouts but that's held in the Fund VI escrow which is not released until the portfolio value exceeds 115% of cost (last at 104% in 4Q and likely declines further in 1Q with the Sprouts exit). We're estimating 3c in cash carry for PE in 1Q as we bake in potential dividend recaps in portfolio companies. APO announced sales of Brit Insurance and Great Wolf in 1Q which we estimate could generate 21c of cash carry but we do not expect these to close until 2Q or 3Q.

**CNS Monitoring fee expired in 4Q, drops to zero in 1Q:** this drives a 29% decline in credit mgmt fee revenues in 1Q15, worth 8c to EPS. We're relatively less concerned about this as it's been expected for some time now and does not impact cash earnings or the dividend... but presents headline risk to reported EPS.

**Founder and significant shareholder lock-ups expired March 29, could**

MORGAN STANLEY & CO. LLC  
Michael J. Cyprys, CFA, CPA

Nicholas Stelzner, CFA

### Apollo Global Management LLC ( APO.N, APO.US )

US Asset Managers / United States of America

**Stock Rating** **Underweight**  
**Industry View** **In-Line**  
**Price target** **\$23.00**  
Shr price, close (Mar 31, 2015) \$21.60  
52-Week Range \$31.59-20.02

Fiscal Year Ending	12/14	12/15e	12/16e	12/17e
<b>ModelWare EPS (\$)</b>	<b>1.42</b>	<b>1.88</b>	<b>2.15</b>	<b>2.27</b>
<b>Prior ModelWare EPS (\$)</b>	-	<b>1.86</b>	<b>2.07</b>	<b>2.22</b>
<b>P/E</b>	<b>16.6</b>	<b>11.5</b>	<b>10.1</b>	<b>9.5</b>
<b>Consensus EPS (\$)<sup>§</sup></b>	<b>1.64</b>	<b>2.01</b>	<b>2.25</b>	-
Div yld (%)	12.3	9.1	8.7	8.1

Unless otherwise noted, all metrics are based on Morgan Stanley ModelWare framework

§ = Consensus data is provided by Thomson Reuters Estimates

e = Morgan Stanley Research estimates

### QUARTERLY MODELWARE EPS (\$)

Quarter	2015e		2016e		2016e	
	2014	Prior	Current	Prior	Current	Current
Q1	0.55	0.38	0.36	0.58	0.60	0.60
Q2	0.52	0.54	0.56	0.55	0.57	0.57
Q3	0.12	0.42	0.43	0.43	0.45	0.45
Q4	0.23	0.51	0.53	0.51	0.53	0.53

e = Morgan Stanley Research estimates

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.

**For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.**


**potentially see insider share sales post black-out period in May:** this is worth 7.6% of sharecount, which could pressure the shares near-term. While it's possible none could sell, history suggests partial selling.

**Where we could be wrong:** higher than expected divi could be driven by 1) dividend recap that may not be reported in the press/loan data services, for which we pencil in 3c, 2) greater monetization of APO's GP stake in funds beyond the beyond the 4c that we model in 1Q for realized investment income, 3) dividend payout greater than 90% of cash earnings using on-balance sheet cash or funded through debt issuance (which we think is highly unlikely), 4) greater than expected management fee-related earnings which we estimate at 19c pre-tax, 15c after-tax, 5) greater net realized cash performance fees from the credit business which we model at \$50m or 12c pre-tax.

**Changes to our Estimates:** Lowering 1Q divi by 38% to 30c and lowering 1Q EPS estimate by 7% to 36c. Our 2015-16 dividend estimates decline by 15%/6% to \$1.96/\$1.88 (that's 6%/13% below cons).

**Apollo Global Management (APO, \$21.60, Underweight, PT \$23)**

Less attractive risk-reward as largely through cash harvesting vs peers; long-term potential in unlocking value from Athene but still early days




Source: Thomson Reuters, Morgan Stanley Research

**\$23** Based on DCF and sum-of-the-parts; back into implied multiple

<b>Bull</b> 11.3x 2016e Bull Case EPS	<b>\$32</b>	<b>Returns more in-line with historical.</b> Fundraising +50% and deployment +25% above base case; faster Athene asset growth; carry taxed as ordinary income.
<b>Base</b> 10.7x 2016e Base Case EPS	<b>\$23</b>	<b>Below historical returns with rising allocations to alternatives:</b> 5% fee-paying AUM CAGR, declining pace of harvesting investments; ramp to full corp. tax rate in 2019-20.
<b>Bear</b> 11.1x 2016e Bear Case EPS	<b>\$15</b>	<b>Challenging exit and investing environment:</b> negative near-term marks on accrued performance fees, delayed exits; returns well below historical average, slower capital deployment and weaker fundraising environment; full corp. tax rate in 2018.

**Exhibit 1: Bull to Bear Drivers**



**Why Underweight?**

- **Less upside relative to our Overweight stocks,** driven by Apollo's early cycle skew. We see lower cash earnings over the next several years as APO harvested its investments earlier than peers (80% thru harvesting vs peers at 45-65% thru) which leaves less upside at this point in APO's cycle.
- **Athene catalyst longer tailed** with IPO potentially delayed to 2016 but we would look to get more positive as cash monetization approaches.
- **Expect lower fundraising** at 19% of AUM in 2015-16 vs. peer average of 30%; this drives fee-paying AUM CAGR of 5% in 2014-17 (below peer avg of 11%)
- Founder and significant shareholder lock-ups expire March 29th (worth 7.6% of share count) could weigh on the stock near-term

**Key Value Drivers**

- **Athene:** IPO as early as 4Q15 but most likely in 2016, resolution of internal control weaknesses, strategic actions should accelerate already strong asset growth; and shifting earnings profile toward fee-related earnings
- **Strategic actions:** including acquisitions to further scale the credit and real estate businesses

**Potential Catalysts**

- Stronger fundraising
- Continued pace of realizations
- Strategic actions
- Potential share buybacks


**Risks to Our Price Target**

- **Upside:** Better FPAuM growth, capital deployment accelerates, better returns
- **Downside:** declining valuations reduce cash earnings (fewer exits or lower multiples); slower deployment

## Headwinds for APO


**Declining performance fee (carry) receivable balance:** this balance sheet receivable represents the amount of performance fees that could be realized in cash if the fund investments were liquidated. During 2014 the balance declined from \$3.49 in 2013 to \$1.31/share with about 70% of the beginning of period balance realized in cash in 2014 worth \$2.33 to cash earnings. A similar 70% realization rate during 2015 would imply cash performance fees of \$0.90 in 2015. This suggests downside risk to our \$1.39 realized cash performance fee estimate (our est implies a 106% realization rate). Deployment in Fund VIII set to pick-up in 2015 (~7% invested and almost 20% committed) but realizations are still a few years away.

**Exhibit 2: EOP Gross Performance Fee (Carry) Receivable Balance (\$MM)**



Source: Company Data, Morgan Stanley Research

**Exhibit 3: EOP Net Performance Fee Receivable Balance Per Share vs. Realized Carry Flow Through Rate**



Note: Realized carry flow through rate is calculated as the net realized carry for the period as a % of the BOP net performance fee (carry) receivable balance; Source: Company Data, Morgan Stanley Research

**Exhibit 4: Net Performance Fee Receivable Balance Per Share Roll Forward**

Net Performance Fee (Carry) Receivable Balance Rollforward					
	2011	2012	2013	2014	2015E
<b>BoP</b>	\$3.41	\$1.39	\$2.64	\$3.49	\$1.31
<b>Add: Fund Apprec</b>	(\$1.10)	\$2.68	\$4.60	\$0.15	\$1.00
<b>Less: Realized Gain</b>	(\$0.92)	(\$1.43)	(\$3.75)	(\$2.33)	(\$1.39)
<b>EoP</b>	\$1.39	\$2.64	\$3.49	\$1.31	\$0.92


  

Flow Through Rate (%): Represents % of BoP Carry Balance that is Realized in Cash					
	2011	2012	2013	2014	2015E
<b>Realized Carry</b>	26.9%	103.0%	142.0%	66.8%	106.2%
<b>Total Carry</b>	-32.3%	193.5%	173.9%	4.3%	76.2%

Note: Realized carry flow through rate is calculated as the net realized carry for the period as a % of the BOP net performance fee (carry) receivable per share balance; Source: Company Data, Morgan Stanley Research

**Fee-paying AUM outflows in credit:** net outflows to fee-paying AUM in credit of -\$475m in 2014 or -0.5%, improved vs outflows of -\$1.5b in 2013 or -3.1%. In our forward look we expect this stabilizes and build in solid growth from Athene. All in, we're expecting about ~\$13b in gross fee-paying inflows in each 2015-16, and on a net basis (net of outflows) we're expecting net inflows of \$9.2b and \$6.1b in 2015-16. Additionally, we're baking in \$3b of additional sub-advised assets from Athene in each 2015-16. Potential upside to estimates if APO successfully scales the newly announced sub-advised relationship with Oppenheimer, but it's still early days and details of the product remain light (questions around specific type of credit products, liquidity provisions for retail, economics, risk mgmt, etc).

**Exhibit 5: Net Organic Fee-Paying AUM Flows in Credit (\$MM)**



Note: Net organic flows in credit are calculated by summing the subscriptions/capital raised, distributions and redemptions lines in FPAuM roll forward table; Source: Company Data, Morgan Stanley Research

**Founder and significant shareholder lock-ups expire March 29th:** this is worth 7.6% of share count which could pressure the shares near-term. While it's possible none could sell, history suggests partial selling.

**CNS Monitoring fee expires in 4Q14, drops to zero in 1Q15:** We flag as a headline risk given the magnitude with an expected 29% decline in credit management fee revenues in 1Q15. This is worth 8c to 1Q15 EPS. But, we're not as concerned about this falling out of the run rate in 1Q15 because it's been expected for some time now and does not impact cash earnings nor the dividend.

# Model Summary

## Exhibit 6: APO Model Summary

Apollo Global Management							Apollo Global Management						
Income Statement (\$MM)							% Growth						
	2012	2013	2014	2015E	2016E	2017E		2012	2013	2014	2015E	2016E	2017E
<b>Revenue</b>													
Management Fees	773	927	1,217	1,015	1,074	1,113	Management Fees	35.0%	19.9%	31.3%	-16.6%	5.8%	3.6%
Performance Fees	2,201	2,896	407	686	830	909	Performance Fees	-654.0%	31.6%	-86.0%	68.7%	21.0%	9.5%
Investment Income	120	102	66	126	154	183	Investment Income	2278.7%	-14.6%	-36.0%	82.7%	21.9%	18.8%
Other Income	21	52	68	12	12	13	Other Income	43.2%	146.9%	29.6%	-82.5%	0.3%	7.4%
<b>Total Revenue</b>	<b>3,116</b>	<b>3,978</b>	<b>1,757</b>	<b>1,839</b>	<b>2,070</b>	<b>2,218</b>	<b>Total Revenue</b>	<b>43.2%</b>	<b>27.7%</b>	<b>-55.8%</b>	<b>4.7%</b>	<b>12.6%</b>	<b>7.1%</b>
<b>Expenses</b>													
Compensation	1,217	1,534	723	697	774	837	Pre-tax Income (Economic Income)	-644.0%	30.2%	-64.5%	13.2%	17.1%	7.3%
Non-Compensation	257	302	266	274	283	292	<b>Net Income (Economic Net Income, or ENI)</b>	<b>-558.9%</b>	<b>34.1%</b>	<b>-71.3%</b>	<b>34.5%</b>	<b>16.8%</b>	<b>7.5%</b>
<b>Total Expenses</b>	<b>1,473</b>	<b>1,836</b>	<b>989</b>	<b>972</b>	<b>1,058</b>	<b>1,129</b>	<b>EPS</b>	<b>-541.7%</b>	<b>31.4%</b>	<b>-71.7%</b>	<b>32.1%</b>	<b>14.5%</b>	<b>5.5%</b>
Pre-tax Income (Economic Income)	1,634	2,128	756	856	1,002	1,076	Average Diluted Share Count	3.9%	2.1%	1.5%	1.8%	2.0%	2.0%
Tax Rate	10%	7%	25%	17%	11%	17%	Dividends Per Share	73.2%	103.3%	-26.7%	-32.2%	-4.2%	-6.3%
Tax Expense	159	149	188	92	110	116	Cash Earnings Per Share (DE Per Unit)	83.4%	119.6%	-30.1%	-30.4%	-4.2%	-6.3%
<b>Net Income (Economic Net Income, or ENI)</b>	<b>1,475</b>	<b>1,979</b>	<b>568</b>	<b>764</b>	<b>893</b>	<b>960</b>	<b>Core Earnings (\$MM)</b>						
<b>EPS</b>	<b>\$ 3.82</b>	<b>\$ 5.02</b>	<b>\$ 1.42</b>	<b>\$ 1.88</b>	<b>\$ 2.15</b>	<b>\$ 2.27</b>	2012	2013	2014	2015E	2016E	2017E	
Average Diluted Share Count	386	394	400	407	415	424	Core Pre-tax Income						
Dividends Per Share	\$ 1.94	\$ 3.94	\$ 2.89	\$ 1.96	\$ 1.88	\$ 1.76	Core FFE	239	337	574	364	400	417
Cash Earnings Per Share (DE Per Unit)	\$ 2.04	\$ 4.48	\$ 3.13	\$ 2.18	\$ 2.00	\$ 1.96	Net Performance Fees	1,291	1,686	89	370	452	479
<b>Pre-tax Income</b>							Core Investment Income	104	104	94	121	150	180
FRE (Mgmt Business)	223	331	578	399	396	414	<b>Core EPS Contribution</b>						
Net performance fees (Incentive Business)	1,411	1,797	178	497	606	662	Core FFE	\$ 0.41	\$ 0.60	\$ 1.02	\$ 0.72	\$ 0.77	\$ 0.79
Investment income	-	-	-	-	-	-	Net Performance Fees	\$ 3.15	\$ 4.16	\$ 0.19	\$ 0.87	\$ 1.03	\$ 1.07
<b>After-tax Income Per Share</b>							Core Investment Income	\$ 0.28	\$ 0.25	\$ 0.21	\$ 0.29	\$ 0.35	\$ 0.41
FRE	\$ 0.38	\$ 0.58	\$ 1.01	\$ 0.71	\$ 0.76	\$ 0.78	<b>Margin Analysis</b>						
Net Performance Fees	\$ 3.44	\$ 4.44	\$ 0.41	\$ 1.17	\$ 1.39	\$ 1.48	2012	2013	2014	2015E	2016E	2017E	
Core Investment Income	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	Revenue						
<b>EPS</b>	<b>\$ 3.82</b>	<b>\$ 5.02</b>	<b>\$ 1.42</b>	<b>\$ 1.88</b>	<b>\$ 2.15</b>	<b>\$ 2.27</b>	Mgmt Fees / Avg FPAUM	1.10%	0.88%	0.95%	0.78%	0.76%	0.76%
<b>Balance Sheet (\$MM)</b>							Performance Fees / Avg FPAUM	3.14%	2.75%	0.32%	0.51%	0.59%	0.62%
Cash	946	1,075	1,204	1,494	1,956	3,083	Investment Income / BoP Investments	34.0%	23.1%	15.5%	14.7%	14.3%	15.1%
Investments	468	510	857	1,078	1,211	1,419	<b>Expenses</b>						
Other	3,044	3,626	2,116	1,890	1,870	2,096	Base Comp / Mgmt Fees	44.5%	38.9%	36.7%	41.1%	40.3%	40.0%
<b>Total Assets</b>	<b>4,458</b>	<b>5,214</b>	<b>4,178</b>	<b>4,460</b>	<b>5,038</b>	<b>6,558</b>	Non-Comp / Mgmt Fees	33.2%	32.6%	21.8%	27.0%	26.3%	26.2%
Debt	738	750	1,034	1,016	1,016	1,016	Perform Comp / Performance Fees	38.7%	40.5%	67.9%	40.7%	41.0%	43.1%
Other	1,719	2,006	1,344	982	751	1,374	<b>Profitability</b>						
<b>Total Liabilities</b>	<b>2,456</b>	<b>2,756</b>	<b>2,379</b>	<b>1,998</b>	<b>1,767</b>	<b>2,390</b>	FRE Margin (FRE / Fee Revenue)	27.5%	34.3%	48.0%	34.2%	35.6%	35.9%
Total Equity	2,002	2,457	1,799	2,461	3,271	4,168	Core FRE Margin (Core FRE / Fee Revenue)	30.9%	36.4%	47.2%	35.9%	37.2%	37.5%
<b>Leverage Ratios</b>							Pre-Tax Margin (Pre-Tax Income / Revenue)	52.4%	53.5%	43.0%	46.5%	48.4%	48.9%
EBITDA / Interest Expense	23.4	64.9	64.8	41.0	40.6	38.9	<b>Company Metrics (\$B)</b>						
Debt / equity	0.37x	0.31x	0.57x	0.41x	0.31x	0.24x	2012	2013	2014	2015E	2016E	2017E	
<b>Cash Earnings Walk (\$MM)</b>							AUM and Flows						
2012	2013	2014	2015E	2016E	2017E	Private Equity	37.8	49.9	41.0	40.5	39.5	36.7	
Pre-Tax Income (Economic net income)	1,634	2,128	756	856	1,002	1,076	Credit	64.4	100.9	108.4	120.5	128.2	141.0
Less: Net performance fees	(1,291)	(1,686)	(86)	(370)	(452)	(479)	Real Estate	8.8	9.3	9.5	9.6	9.9	9.9
Less: Investment income (loss)	(120)	(102)	(66)	(126)	(154)	(183)	Total AUM	111.0	160.1	158.0	170.6	177.6	187.5
Less: Other income	-	(9)	(23)	-	-	-	Private Equity	27.9	34.2	30.3	30.1	28.8	26.0
<b>Fee related earnings (APO Method)</b>	<b>223</b>	<b>331</b>	<b>578</b>	<b>399</b>	<b>396</b>	<b>414</b>	Credit	49.5	66.2	92.2	101.7	108.1	119.2
Add: Realized perf fees, net of related comp	552	1,479	931	567	538	467	Real Estate	4.5	5.9	6.2	6.1	6.2	5.7
Add: Investment income (loss) realized	-	108	64	62	47	47	Total FPAUM	81.9	128.4	128.7	137.9	143.0	150.9
Less: Athene capital and surplus fees	-	(119)	(228)	-	-	-	Fundraising	6.6	22.1	9.9	14.9	14.8	15.5
Add: Equity-based comp (non-cash item)	69	66	107	72	72	76	Harvesting & Outflows	(12.1)	(24.0)	(17.1)	(14.5)	(15.6)	(13.8)
Add: Dep and amort (non-cash item)	10	11	10	10	10	10	Net flows to AUM	(5.4)	(1.8)	(7.2)	0.5	(0.8)	1.8
Add: Other	(21)	(13)	(32)	-	-	-	Deployment	4.8	7.0	10.0	10.8	12.9	16.8
<b>Cash Earnings (DE) (pre-tax)</b>	<b>833</b>	<b>1,871</b>	<b>1,430</b>	<b>1,070</b>	<b>1,064</b>	<b>1,014</b>	Dry Powder	7.5	31.8	32.1	31.3	29.9	23.7
Add: Interest expense	37	29	22	27	27	27	<b>AUM Sequential Growth</b>						
<b>Total EBITDA (Excludes MTM Gains)</b>	<b>870</b>	<b>1,901</b>	<b>1,452</b>	<b>1,097</b>	<b>1,090</b>	<b>1,040</b>	FPAUM Sequential Growth	47.6%	44.2%	-0.7%	7.3%	4.1%	5.6%
Less: Realized Net perf fees and inv income	(552)	(1,586)	(995)	(629)	(585)	(514)	Fundraising / BoP AUM	8.8%	19.9%	8.2%	9.4%	8.7%	8.8%
<b>Fee and Yield EBITDA (ex eqty-based comp)</b>	<b>318</b>	<b>314</b>	<b>457</b>	<b>468</b>	<b>505</b>	<b>527</b>	Outflows + Realizations / BoP AUM	-16.1%	-21.6%	-10.7%	-9.1%	-9.2%	-7.8%
<b>Cash Earnings Per Share to Public Float</b>							Net Flows / BoP AUM	-7.2%	-1.7%	-4.5%	0.3%	-0.5%	1.0%
Net FFE	\$ 0.66	\$ 0.50	\$ 0.67	\$ 0.76	\$ 0.82	\$ 0.86	Net Flows / BoP FPAUM	2.1%	12.9%	-2.6%	3.6%	2.0%	4.1%
Net realized cash carry	\$ 1.36	\$ 3.71	\$ 2.29	\$ 1.27	\$ 1.17	\$ 0.99	<b>Performance</b>						
Realized investment income	\$ -	\$ 0.27	\$ 0.16	\$ 0.14	\$ 0.10	\$ 0.10	Mkt Appreciation / BoP AUM ex Dry Powder	17.8%	18.5%	2.0%	7.1%	5.5%	5.3%
							PE Appreciation	38.2%	41.2%	2.6%	14.5%	15.9%	16.5%
							RE Appreciation	3.6%	1.4%	-0.7%	8.3%	8.5%	23.0%
							Credit Carry Fund Appreciation	30.7%	8.6%	2.6%	7.6%	8.8%	7.9%

Source: Company Data, Morgan Stanley Research

## Valuation and Risks

---

**Alternative Asset Managers:** We value the stocks using a sum of the parts valuation supported by a discounted cash flow. Our DCF (COE of 11–14%, free cash flow = distributable earnings, terminal growth rate = 3% and betas benchmarked off BX's 1.6x) captures the long-term value of the business model, while the sum of the parts captures some of the shorter-term volatility. For our SOTP, we use 2016 "Core" FRE and apply a 15x multiple which is a 1-2 turn premium to traditionals reflecting value in long term locked up capital; apply 12x multiple on BDC income share; use DCF to estimate future carry and apply discount rate to represent volatile nature of carry; 10% haircut on accrued carry; 10% haircut on B/S assets.

**Apollo Global Management:** Upside risks include better FPAuM growth, accelerated capital deployment, and better returns. Downside risks: declining valuations reduce cash earnings (fewer exits or lower multiples); slower deployment.

## Disclosure Section

The information and opinions in Morgan Stanley Research were prepared by Morgan Stanley & Co. LLC, and/or Morgan Stanley C.T.V.M. S.A., and/or Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., and/or Morgan Stanley Canada Limited. As used in this disclosure section, "Morgan Stanley" includes Morgan Stanley & Co. LLC, Morgan Stanley C.T.V.M. S.A., Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., Morgan Stanley Canada Limited and their affiliates as necessary.

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at [www.morganstanley.com/researchdisclosures](http://www.morganstanley.com/researchdisclosures), or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.

For valuation methodology and risks associated with any price targets referenced in this research report, please contact the Client Support Team as follows: US/Canada [REDACTED]; Hong Kong +852 2848-5999; Latin America [REDACTED] (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.

### Analyst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Michael Cyprys.

Unless otherwise stated, the individuals listed on the cover page of this report are research analysts.

### Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at [www.morganstanley.com/institutional/research/conflictolicies](http://www.morganstanley.com/institutional/research/conflictolicies).

### Important US Regulatory Disclosures on Subject Companies

As of February 27, 2015, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: **Apollo Global Management LLC**, BlackRock Inc., KKR & CO. L.P., Oaktree Capital Group, LLC, The Blackstone Group L.P., The Carlyle Group L.P., WisdomTree Investments, Inc..

Within the last 12 months, Morgan Stanley managed or co-managed a public offering (or 144A offering) of securities of **Apollo Global Management LLC**, Ares Management, L.P., Franklin Resources Inc., Invesco, KKR & CO. L.P., Legg Mason Inc., Oaktree Capital Group, LLC, OM Asset Management Plc, The Blackstone Group L.P., The Carlyle Group L.P..

Within the last 12 months, Morgan Stanley has received compensation for investment banking services from **Apollo Global Management LLC**, Ares Management, L.P., BlackRock Inc., Franklin Resources Inc., Invesco, KKR & CO. L.P., Legg Mason Inc., Oaktree Capital Group, LLC, OM Asset Management Plc, The Blackstone Group L.P., The Carlyle Group L.P., Virtus Investment Partners Inc..

In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from AllianceBernstein Holding L.P., **Apollo Global Management LLC**, Ares Management, L.P., BlackRock Inc., Franklin Resources Inc., Invesco, KKR & CO. L.P., Legg Mason Inc., LPL Investment Holdings Inc., Oaktree Capital Group, LLC, OM Asset Management Plc, T. Rowe Price Group, Inc., The Blackstone Group L.P., The Carlyle Group L.P., Virtus Investment Partners Inc., Waddell & Reed Financial Inc, WisdomTree Investments, Inc..

Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from AllianceBernstein Holding L.P., **Apollo Global Management LLC**, Ares Management, L.P., BlackRock Inc., Federated Investors, Inc., Franklin Resources Inc., Invesco, Janus Capital Group Inc., KKR & CO. L.P., Legg Mason Inc., LPL Investment Holdings Inc., Oaktree Capital Group, LLC, OM Asset Management Plc, T. Rowe Price Group, Inc., The Blackstone Group L.P., The Carlyle Group L.P., Virtus Investment Partners Inc., Waddell & Reed Financial Inc, WisdomTree Investments, Inc..

Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: AllianceBernstein Holding L.P., **Apollo Global Management LLC**, Ares Management, L.P., BlackRock Inc., Franklin Resources Inc., Invesco, KKR & CO. L.P., Legg Mason Inc., LPL Investment Holdings Inc., Oaktree Capital Group, LLC, OM Asset Management Plc, T. Rowe Price Group, Inc., The Blackstone Group L.P., The Carlyle Group L.P., Virtus Investment Partners Inc., Waddell & Reed Financial Inc, WisdomTree Investments, Inc..

Within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: AllianceBernstein Holding L.P., **Apollo Global Management LLC**, Ares Management, L.P., BlackRock Inc., Federated Investors, Inc., Franklin Resources Inc., Invesco, Janus Capital Group Inc., KKR & CO. L.P., Legg Mason Inc., LPL Investment Holdings Inc., Oaktree Capital Group, LLC, OM Asset Management Plc, T. Rowe Price Group, Inc., The Blackstone Group L.P., The Carlyle Group L.P., Virtus Investment Partners Inc., Waddell & Reed Financial Inc, WisdomTree Investments, Inc..

Morgan Stanley & Co. LLC makes a market in the securities of AllianceBernstein Holding L.P., **Apollo Global Management LLC**, BlackRock Inc., Federated Investors, Inc., Franklin Resources Inc., Invesco, Janus Capital Group Inc., KKR & CO. L.P., Legg Mason Inc., LPL Investment Holdings Inc., Oaktree Capital Group, LLC, T. Rowe Price Group, Inc., The Blackstone Group L.P., The Carlyle Group L.P., Virtus Investment Partners Inc., Waddell & Reed Financial Inc, WisdomTree Investments, Inc..

The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues.

Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity and specialized trading, risk arbitrage and other proprietary trading, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

### STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

### Global Stock Ratings Distribution

(as of March 31, 2015)

For disclosure purposes only (in accordance with NASD and NYSE requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond

Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.

STOCK RATING CATEGORY	COVERAGE UNIVERSE		INVESTMENT BANKING CLIENTS (IBC)		
	COUNT	% OF TOTAL	COUNT	% OF TOTAL	% OF RATING CATEGORY
Overweight/Buy	1164	35%	331	43%	28%
Equal-weight/Hold	1466	44%	353	46%	24%
Not-Rated/Hold	100	3%	11	1%	11%
Underweight/Sell	605	18%	80	10%	13%
<b>TOTAL</b>	<b>3,335</b>		<b>775</b>		

Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months.

**Analyst Stock Ratings**

Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Not-Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

**Analyst Industry Views**

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.


In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.

Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below.

Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

**Stock Price, Price Target and Rating History (See Rating Definitions)**

Apollo Global Management LLC (APO.N) - As of 3/31/15 in USD  
Industry : US Asset Managers



Stock Rating History: 3/1/12 : NR/I; 9/11/13 : O/I; 11/8/13 : E/I; 1/16/14 : NA/I; 2/26/14 : E/I; 5/12/14 : NA/I; 12/15/14 : U/I

Price Target History: 9/11/13 : 33; 11/13/13 : 34; 1/16/14 : NA; 2/26/14 : 34; 5/12/14 : NA; 12/15/14 : 24; 3/12/15 : 23

Source: Morgan Stanley Research Date Format : MM/DD/YY Price Target -- No Price Target Assigned (NA)  
 Stock Price (Not Covered by Current Analyst) — Stock Price (Covered by Current Analyst) —  
 Stock and Industry Ratings (abbreviations below) appear as ♦ Stock Rating/Industry View  
 Stock Ratings: Overweight (O) Equal-weight (E) Underweight (U) Not-Rated (NR) No Rating Available (NA)  
 Industry View: Attractive (A) In-line (I) Cautious (C) No Rating (NR)

Effective January 13, 2014, the stocks covered by Morgan Stanley Asia Pacific will be rated relative to the analyst's industry (or industry team's) coverage.

Effective January 13, 2014, the industry view benchmarks for Morgan Stanley Asia Pacific are as follows: relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

## Important Disclosures for Morgan Stanley Smith Barney LLC Customers

Important disclosures regarding the relationship between the companies that are the subject of Morgan Stanley Research and Morgan Stanley Smith Barney LLC or Morgan Stanley or any of their affiliates, are available on the Morgan Stanley Wealth Management disclosure website at [www.morganstanley.com/online/researchdisclosures](http://www.morganstanley.com/online/researchdisclosures). For Morgan Stanley specific disclosures, you may refer to [www.morganstanley.com/researchdisclosures](http://www.morganstanley.com/researchdisclosures).

Each Morgan Stanley Equity Research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval is conducted by the same person who reviews the Equity Research report on behalf of Morgan Stanley. This could create a conflict of interest.

### Other Important Disclosures

Morgan Stanley & Co. International PLC and its affiliates have a significant financial interest in the debt securities of BlackRock Inc., Franklin Resources Inc., Janus Capital Group Inc., Legg Mason Inc., OM Asset Management Plc.

Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at <http://www.morganstanley.com/matrix>.

Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third-party vendors or redistributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at <http://www.morganstanley.com/matrix>.

Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use (<http://www.morganstanley.com/terms.html>). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use (<http://www.morganstanley.com/terms.html>). In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy ([http://www.morganstanley.com/privacy\\_pledge.html](http://www.morganstanley.com/privacy_pledge.html)), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy ([http://www.morganstanley.com/privacy\\_pledge.html](http://www.morganstanley.com/privacy_pledge.html)).

If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies please do not access our research.

Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

The "Important US Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.

Morgan Stanley may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

To our readers in Taiwan: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments. To our readers in Hong Kong: Information is distributed in Hong Kong by and on behalf of, and is attributable to, Morgan Stanley Asia Limited as part of its regulated activities in Hong Kong. If you have any queries concerning Morgan Stanley Research, please contact our Hong Kong sales representatives.

Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves.

Morgan Stanley Research is disseminated in Brazil by Morgan Stanley C.T.V.M. S.A.; in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents) and by Bank Morgan Stanley AG, Hong Kong Branch; in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research) and by Bank Morgan Stanley AG, Singapore Branch (Registration number T11FC0207F); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" and "retail clients" within the meaning of the Australian Corporations Act by Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No.

240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited; in Indonesia by PT Morgan Stanley Asia Indonesia; in Canada by Morgan Stanley Canada Limited, which has approved of and takes responsibility for its contents in Canada; in Germany by Morgan Stanley Bank AG, Frankfurt am Main and Morgan Stanley Private Wealth Management Limited, Niederfassung Deutschland, regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin); in Spain by Morgan Stanley, S.V., S.A., a Morgan Stanley group company, which is supervised by the Spanish Securities Markets Commission (CNMV) and states that Morgan Stanley Research has been written and distributed in accordance with the rules of conduct applicable to financial research as established under Spanish regulations; in the US by Morgan Stanley & Co. LLC, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized by the Prudential Regulatory Authority and regulated by the Financial Conduct Authority and the Prudential Regulatory Authority, disseminates in the UK research that it has prepared, and approves solely for the purposes of section 21 of the Financial Services and Markets Act 2000, research which has been prepared by any of its affiliates. Morgan Stanley Private Wealth Management Limited, authorized and regulated by the Financial Conduct Authority, also disseminates Morgan Stanley Research in the UK. Private UK investors should obtain the advice of their Morgan Stanley & Co. International plc or Morgan Stanley Private Wealth Management representative about the investments concerned. RMB Morgan Stanley (Proprietary) Limited is a member of the JSE Limited and regulated by the Financial Services Board in South Africa. RMB Morgan Stanley (Proprietary) Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited. The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA), and is directed at Professional Clients only, as defined by the DFSA. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria to be a Professional Client. The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations. The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P. Morgan Stanley Research or portions of it may not be reprinted, sold or redistributed without the written consent of Morgan Stanley. Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

#### INDUSTRY COVERAGE: US Asset Managers

COMPANY (TICKER)	RATING (AS OF)	PRICE* (03/31/2015)
<b>Cyprys CFA, CPA, Michael J.</b>		
Apollo Global Management LLC (APO.N)	U (12/15/2014)	\$21.60
Ares Management, L.P. (ARES.N)	E (12/15/2014)	\$18.54
KKR & CO. L.P. (KKR.N)	O (12/15/2014)	\$22.81
Oaktree Capital Group, LLC (OAK.N)	O (12/15/2014)	\$51.66
The Blackstone Group L.P. (BXN)	O (12/15/2014)	\$38.89
The Carlyle Group L.P. (CG.O)	E (12/15/2014)	\$27.10
<b>Grasbeck CFA, Betsy L.</b>		
BlackRock Inc. (BLK.N)	O (05/12/2014)	\$365.84
Franklin Resources Inc. (BEN.N)	E (05/12/2014)	\$51.32
Invesco (IVZ.N)	E (05/12/2014)	\$39.69
OM Asset Management Plc (OMAMN)	O (11/18/2014)	\$18.64
T. Rowe Price Group, Inc. (TROW.O)	E (05/12/2014)	\$80.98
<b>Whitehead CFA, Thomas</b>		
AllianceBernstein Holding L.P. (AB.N)	E (05/12/2014)	\$30.87
Federated Investors, Inc. (FILN)	U (05/12/2014)	\$33.89
Janus Capital Group Inc. (JNS.N)	E (09/29/2014)	\$17.19
Legg Mason Inc. (LMN)	E (05/12/2014)	\$55.20
LPL Investment Holdings Inc. (LPLA.O)	E (05/12/2014)	\$43.86
Virtus Investment Partners Inc. (VRTS.O)	E (05/12/2014)	\$130.77
Waddell & Reed Financial Inc (WDR.N)	E (05/12/2014)	\$49.54
WisdomTree Investments, Inc. (WETF.O)	O (06/09/2014)	\$21.46

Stock Ratings are subject to change. Please see latest research for each company.

\* Historical prices are not split adjusted.